Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
US Army
Boehringer Ingelheim
AstraZeneca
Merck
US Department of Justice
Cipla
Dow
Harvard Business School

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,486,972

« Back to Dashboard

Which drugs does patent 8,486,972 protect, and when does it expire?

Patent 8,486,972 protects SUBSYS and is included in one NDA.

This patent has eighteen patent family members in fifteen countries.
Summary for Patent: 8,486,972
Title:Sublingual fentanyl spray
Abstract: The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable salt thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations.
Inventor(s): Kottayil; S. George (Long Grove, IL), Goskonda; Venkat R. (Gurnee, IL), Zhu; Zhongyuan (Vernon Hills, IL), Parikh; Neha (Chicago, IL), Kattookaran; Linet (Mount Prospect, IL)
Assignee: Insys Therapeutics, Inc. (Phoenix, AZ)
Application Number:11/698,739
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound;

Drugs Protected by US Patent 8,486,972

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Insys Dev Co Inc SUBSYS fentanyl SPRAY;SUBLINGUAL 202788-001 Jan 4, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Insys Dev Co Inc SUBSYS fentanyl SPRAY;SUBLINGUAL 202788-002 Jan 4, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Insys Dev Co Inc SUBSYS fentanyl SPRAY;SUBLINGUAL 202788-003 Jan 4, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Insys Dev Co Inc SUBSYS fentanyl SPRAY;SUBLINGUAL 202788-004 Jan 4, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,486,972

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,642,797 Sublingual fentanyl spray and methods of use to treat pain ➤ Sign Up
8,835,460 Sublingual fentanyl spray and methods of treating pain ➤ Sign Up
9,289,387 Method of treating pain by administering sublingual fentanyl spray ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Merck
Cipla
Teva
Chinese Patent Office
Citi
Covington
Mallinckrodt
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.